In patients with type 2 diabetes, lixisenatide met HbA1c noninferiority versus once-daily glulisine, with both reaching 7.2% at 26 weeks.
In plain wordsIn patients with diabetes, lixisenatide met the HbA1c noninferiority criterion compared with once-daily glulisine.
- Peptide
- Lixisenatide
- Outcome
- Direction not reportedHbA1c versus once-daily glulisine
- Study
n: not reported in source
- Comparator
- Insulin glulisine once daily
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- Dose not stated
Measurements
- HbA1c at coprimary endpoint
- 7.2%
- lixisenatide
- HbA1c at coprimary endpoint
- 55 mmol/mol
- lixisenatide
- HbA1c at coprimary endpoint
- 7.2%
- glulisine once daily
- HbA1c at coprimary endpoint
- 55 mmol/mol
- glulisine once daily
Source sentences
HbA1c improved from 8.5% to 7.9% (69 to 63 mmol/mol) with glargine optimization and further to 7.2%, 7.2%, and 7.0% (55, 55, and 53 mmol/mol) with lixisenatide and glulisine once daily and thrice daily, respectively; all coprimary end points were met.
2 context sentences(design, population, supporting numbers)
Coprimary end points at 26 weeks were 1) noninferiority (95% CI upper bound <0.4% [<4.4 mmol/mol]) in HbA1c reduction with lixisenatide versus glulisine once daily, and either 2a) noninferiority in HbA1c reduction for lixisenatide versus glulisine thrice daily or 2b) superiority in body weight chang…
Patients were randomized to lixisenatide once daily or insulin glulisine given once or thrice daily, added to glargine, with or without metformin, if HbA1c remained ≥7 to ≤9% (≥53 to ≤75 mmol/mol) after 12 weeks of glargine optimization with OADs other than metformin stopped at the start of optimization.